US-based bioalternatives scale-up platform, Manus, has opened its new, purpose-built application hub in Singapore to support customers and partners across the Asia-Pacific region.
With the growing demand for sustainable and high-performance ingredients, Manus’ Singapore BioFacility responds to the critical needs of a market facing volatile agricultural supply chains and a strong consumer shift towards natural and clean-label products.
The fully operational regional facility is designed to be a centre for direct partnership, helping customers bring advanced bioalternatives to market through hands-on product development, formulation optimisation, and application-focused problem-solving tailored to local needs.
Bioalternative ingredients have been a hot topic in Australia recently – becoming the fourth country in the world to approve cell-cultured meat for human consumption in June 2025. The landmark decision from FSANZ opened the gates for Eden Brew to submit its precision-fermented milk protein, and cell cultured duck from European company Suprême SAS (Gourmey) to begin the approval process.
Infrastructure in the country is also improving, with the Queensland University of Technology (QUT) completing an $18 million upgrade of its Mackay-based QUT Pioneer BioPilot in September, and Cauldron Ferm and the Queensland government currently developing a precision fermentation contract manufacturing facility in the same area.
The new Manus facility is located in Singapore, the very first country to approve cultured meat for sale back in 2020. The company stated Singapore's unique position as a hub for innovation, with its exceptional regional connectivity and deep technical talent, provides the ideal ecosystem.
Manus vice president global food ingredients – application and customer technical services, Gary Tan, said teams will work side by side with customers in the company’s application lab to test, refine, and adapt formulations to regional requirements, performance expectations, and end-use applications before scaling.
“This hands-on approach helps ensure Manus products perform as intended in real-world applications,” said Tan.
The collaborative model provides partners with a low-risk pathway to integrate advanced biobased solutions, accelerating time-to-market.
The Singapore BioFacility is the latest addition to Manus’ end-to-end biomanufacturing platform, joining the company's R&D and innovation hubs in Boston, Massachusetts, and Pleasanton, California, and its large-scale bioalternatives production facility in Augusta, Georgia.
By establishing a local presence, Manus aims to offer industry leaders a direct pathway to build smarter, more agile, and sustainable products. The company is inviting companies across the Asia-Pacific region to connect and explore how its products and collaborative approach can help them realise the benefits of biomanufacturing.
